Introduction
Systemic sclerosis, a chronic disease of unknown etiology, is characterized by vascular injury, autoimmune inflammatory responses and tissue fibrosis (Jimenez and Derk, 2004) . Multiple cytokines and growth factors that can induce fibroblast activation have been implicated in the pathogenesis of fibrosis (Varga and Abraham, 2007) . Of these, transforming growth factor-b (TGF-b) plays a pivotal role by driving the upregulation of collagen synthesis, epithelial-mesenchymal transition and myofibroblasts transdifferentiation (Varga and Trojanowska, 2008) . In fibroblasts, the Smad pathway serves as the best characterized signal transduction mechanism for TGF-b. Canonical Smad signaling is activated upon TGF-b binding to the type 2 transmembrane receptors (TbRII), leading to phosphorylation of type 1 TGF-b receptors (TbRI) and activation of cytoplasmic Smad2 and Smad3. Activated Smad2/3 then forms a complex with Smad4 and accumulates within the nucleus where it binds to consensus Smadbinding element (SBE) sequences to activate transcription (Massague´et al., 2005) . Recent studies also provide substantial evidence for the important roles of nonSmad signaling pathways in mediating TGF-b responses (Moustakas et al., 2005) . These include several MAP kinases, TAK1 and as we recently showed, early growth response-1 (Egr-1) (Wenner and Yan, 2003; Pannu and Trojanowska, 2004; Javelaud and Mauviel, 2005; Bhattacharyya et al., 2008) . Establishing the association of distinct signal transduction pathways with particular TGF-b responses is important for gaining further insights into TGF-b biology, and for the development of anti-TGF-b therapies selectively targeting profibrotic responses.
The c-Abelson (c-Abl) oncogene, a member of the Src family of nonreceptor protein tyrosine kinases, regulates cell proliferation, cytoskeletal remodeling and apoptosis in response to DNA damage and stress (Kharbanda et al., 1995a (Kharbanda et al., , b, 1997 . Transforming mutations of c-Abl are found in 95% of patients with chronic myelogenous leukemia (CML) (Groffen et al., 1984) . The Philadelphia chromosome, a hallmark of CML, represents reciprocal translocation of the Abl gene from chromosome 9 to the breakpoint cluster region of chromosome 22 t(9;22). This translocation results in the fusion protein Bcr-Abl (breakpoint cluster region Abelson leukemia), which has constitutive tyrosine kinase activity and is directly implicated in causing leukemic transformation, presumably through phosphorylation of multiple protein targets, resulting in aberrant activation of mitogenic pathways (Rowley, 1973; Lugo et al., 1990) . Imatinib mesylate (Gleevec), a small molecule kinase inhibitor active against c-Abl as well as Bcr-Abl, suppresses the growth of Bcr-Abexpressing progenitor cells, and induces in >70% stable cytogenetic remission of cases of CML (Druker et al., 1996; Deininger et al., 1997; La Rose´e et al., 2002; Goldman and Melo, 2003) . Recent studies of c-Abl function in nonmyeloid cell types reveal that in mesenchymal cells, but not in epithelial cells, c-Abl integrates TGF-b-induced serine/threonine receptor kinase signaling with tyrosine kinase pathways (Wilkes and Leof, 2006) . Inhibition of c-Abl by imatinib was shown to abrogate the stimulation of collagen gene expression in vitro, and to prevent the development of tissue fibrosis in vivo in a variety of animal models (Daniels et al., 2004; Wang et al., 2005; Wilkes and Leof, 2006; Distler et al., 2007) . It has been proposed that the ablation of TGF-b signaling with imatinib and related inhibitors of c-abl tyrosine kinase might usher in a new era in the treatment of fibrosis (Rosenbloom and Jime´nez, 2008) . Despite the emerging evidence implicating c-Abl in the stimulation of collagen synthesis and fibrotic responses, however the underlying molecular basis, and the mediators downstream of c-Abl, are not well understood.
These studies were therefore undertaken to characterize the involvement of c-Abl in TGF-b-mediated stimulation of collagen synthesis, focusing on the potential role of Egr-1. Here, we report that constitutively active Abl not only stimulated collagen gene expression in normal fibroblasts, but also directly induced Egr-1 expression and transcriptional activity in the absence of added TGF-b. Induction of Egr-1 by Abl occurred through an ERK (extracellular regulated kinase)-dependent signaling mechanism, and was necessary for the stimulation of collagen gene expression. Bleomycin-induced scleroderma in the mouse was associated with the accumulation of phosphorylated c-Abl within fibrotic dermis, and closely correlated with increased expression of Egr-1 in situ. These results lead us to propose a novel model for fibrogenesis in which TGF-b-induced activation of c-Abl results in enhanced Egr-1 expression and consequent fibrotic cellular responses.
Results
Abl activation is sufficient and necessary for enhanced collagen gene expression In immortalized cell lines, activated c-Abl has been shown previously to mediate the induction of fibrotic responses, such as stimulation of the synthesis of collagen and fibronectin (Daniels et al., 2004; Wilkes and Leof, 2006; Distler et al., 2007) . It was important to examine the role of c-Abl in the regulation of collagen synthesis in nontransformed primary cultures of fibroblasts. Transfection of foreskin fibroblasts with expression plasmids for Bcr-Abl, a fusion protein with a constitutively active Abl tyrosine kinase domain, resulted in a marked increase in Type I collagen levels with a magnitude comparable to TGF-b (Figure 1a (Figure 3d ). Rescue with wild-type c-Abl not only enhanced the basal levels of collagen synthesis and mRNA expression, but also restored TGF-b-induced stimulation in these cells (Figures 4a and b) . In marked contrast, a kinaseinactive mutant, c-Abl, failed to restore TGF-b sensitivity. Collectively, these gain-of-function and loss-offunction experiments implicate Abl as both sufficient and necessary for stimulation of collagen gene expression in primary fibroblasts, firmly establishing a functional role for tyrosine kinase signaling in this TGF-b response.
As observed previously in NIH3T3 and IMR90 fibroblastic line (Daniels et al., 2004) , stimulation of primary fibroblasts by TGF-b induced a marked increase in c-Abl kinase activity within 15 min and peaking at 60 min (Figure 5a ). Furthermore, cellular c-Abl was phosphorylated on Tyr-245 in parallel with phosphorylation of Smad2 (Figure 5b ). c-Abl is thus a direct target of TGF-b that is necessary and sufficient for stimulation of collagen synthesis in primary fibroblasts.
Smad2/3-independent inhibition of TGF-b signaling by imatinib mesylate As downstream targets for activated ALK5 in fibroblasts, Smad2 and Smad3 serve as the principal signal transducers for TGF-b stimulation of collagen and related profibrotic genes (Chen et al., 1999) . Interstingly, the inhibitory effect of imatinib on collagen synthesis was independent of TGF-b-induced phosphorylation and nuclear accumulation of Smad3 or Smad4 (Figures 6a upper panel and 6c, and data not shown), or of binding of activated Smad2/3 to SBE sequences ( Figure 6b ). Furthermore, Smad2/3 nuclear accumulation was comparable in Abl To further examine the effect of Bcr-Abl on Egr-1 activation, Egr-1 DNA binding to its functional recognition sites in the COL1A2 promoter was examined in intact cells. Foreskin fibroblasts expressing ectopic Bcr-Abl were cross-linked with formaldehyde, and chromatin was subjected to chromatin immunoprecipitation analysis. Whereas little Egr-1 was detected on the COL1A2 promoter in control fibroblasts expressing empty vector, a marked increase in Egr-1 binding to the COL1A2 promoter was noted in fibroblasts harboring ectopic Bcr-Abl, and imatinib treatment of the cultures abrogated this increase (Figure 8d ). Together, these results indicate that Abl directly induces cellular Egr-1 activation, which in turn mediates the stimulation of collagen gene expression.
Bleomycin-induced fibrosis is associated with elevated phospho-cAbl expression in situ Because little is known regarding Abl activation in the context of fibrosis, we examined the levels of phosphorylated c-Abl in a mouse model of scleroderma. Subcutaneous injections of bleomycin in BALB/c mice resulted in the development of scleroderma-like skin changes with dense fibrosis of the dermis. We have shown previously that TGF-b plays a pivotal role in the pathological changes in this model of scleroderma (Takagawa et al., 2003) . Dermal fibrosis was accompanied approximately by a twofold increase in the levels of phosphorylated c-Abl in lesional tissue compared witrh phosphate-buffered saline (PBS)-injected control mice ( Figure 9 ). Immunostaining was principally localized in fibroblasts in the deeper dermis, and was specific, as substitution of the primary antibody with rabbit IgG resulted in the absence of brown staining. To show a correlation between the expression of phosphocAbl and Egr-1 in this model of fibrosis, simultaneous immunostaining for Egr-1 was performed. In contrast to PBS-treated mice that had little or no Egr-1 was detected in the dermis, a significant proportion of fibroblastic cells in lesional dermis showed strong positive Egr-1 immunostaining localized within the nucleus. The topological distribution of Egr-1-positive fibroblasts in the lesional dermis closely paralleled the distribution of phospho-cAbl. Cellular Abl regulates important processes including actin reorganization, differentiaition and apoptosis following DNA damage (Kharas and Fruman, 2005) . The biological activity of c-Abl is normally tightly controlled, and aberrant Abl kinase activity is directly responsible for the leukemic transformation of myeloid cells in CML. Genotoxic and oxidative stress, as well as platelet derived growth factor (PDGF), induce c-Abl activation (Lewis et al., 1996; Van Etten, 1999; Schubert et al., 2007) . These results indicate that in normal skin fibroblasts TGF-b stimulated the kinase activity of cAbl, and blockade of c-Abl prevented cellular responses induced by TGF-b independent of Smad activation. The present findings are in good agreement with recent reports in NIH3T3 and IMR90 cells (Daniels et al., 2004) . The induction of c-Abl kinase activity in response to TGF-b occurred in mesenchymal cells but not in epithelial cells, and was shown to involve the PI3 kinase and p21-activated kinase 2 PAK2 (Wilkes and Leof, 2006) . Furthermore, in contrast to canonical Smaddependent TGF-b responses, induction of c-Abl was not dependent on internalization of the TGF-b receptor. Although the mediators upstream of c-Abl activation have been well characterized, those downstream of c-Abl in the context of fibrogenesis are not well understood.
In agreement with earlier studies, we found that pretreatment of fibroblasts with imatinib did not abrogate activation of Smad2/3 induced by TGF-b. A recent report indicated that imatinib blocked the phosphorylation of Smad1 induced by TGF-b (Pannu et al., 2008) . Smad1 activation by TGF-b was originally described in endothelial cells, where the response involved both the ALK5 and ALK1 TGF-b receptors (Goumans et al., 2002) . Subsequent reports have established that Smad1 can be activated in mesenchymal cells, and may play a role in fibrosis (Takahashi et al., 2005; Pannu et al., 2007 Pannu et al., , 2008 ).
In our study, the stimulation of Egr-1 was prevented by imatinib, thereby locating Egr-1 downstream of activated c-Abl. The early immediate Egr-1 gene product is a zinc finger transcription factor readily induced by a variety of environmental stimuli. Target genes that are directly regulated by Egr-1 include PDGF, TGF-b, PTEN and collagen (Svaren et al., 2000; Virolle et al., 2001; Chen et al., 2006) . Rapid and generally transient Egr-1 induction plays an important role in orchestrating acute tissue responses to injury (Gashler and Sukhatme, 1995; Khachigian, 2006) . We have shown previously in skin and lung fibroblasts that Egr-1 was also induced by TGF-b (Chen et al., 2006; Bhattacharyya et al., 2008) . Importantly, Egr-1 in these cells was sufficient and necessary for stimulation of collagen gene expression. The mechanism for the induction of Egr-1 by TGF-b has been only partially elucidated. We showed that TGF-b stimulated the transcription of the Egr-1 gene, and the response was insensitive to SB431542, a selective inhibitor of ALK5-mediated Smad2/3 activation (Mori et al., 2004) . Rather, TGF-b was shown to activate the MEK1-ERK1/2 signaling cascade converging on the ternary transcription factor Elk-1 and multiple SRE elements in the Egr-1 promoter (Buchwalter et al., 2004) . These results further delineate the mechanism of Egr-1 induction by showing that in the absence of exogenously added TGF-b, Abl was sufficient to induce Egr-1 gene expression, DNA binding and transcriptional activity. This is not the first indication that Abl regulates the expression of Egr-1. In an earlier study, DNA microarray analysis of ectopic c-Abl expression in 293 epithelial cells identified Egr-1 as a novel target (Stuart et al., 2005) . Stimulation of Egr-1 was attenuated by a selective inhibitor of MEK/ERK signaling. Moreover, c-Abl has been shown to directly activate MEK kinase 1 in response to DNA damage (Yoshida et al., 2000) . The essential role of the Abl-Egr-1 pathway in stimulation of collagen gene expression was confirmed with complementary experiments in Egr-1 À/À fibroblasts where BcrAbl failed to stimulate COL1A1 mRNA expression and Type I collagen synthesis.
In addition to leukemogenesis, Abl family kinases play important roles in the regulation of diverse cellular processes including cell proliferation, survival, differentiation and migration (Herna´ndez et al., 2004) . Accumulating evidence now implicates c-Abl in the regulation of connective tissues turnover during both physiological tissue remodeling and in pathological fibrosis. The activity of c-Abl is induced not only by DNA damaging agents, but also by stimuli generated during tissue injury and repair such as PDGF as well as TGF-b, both of which play important roles in fibrogenesis (Bonner, 2004; Leask, 2008) . c-Abl has been shown to directly induce the synthesis of fibronectin, collagen and connective tissue growth factor (Teckchandani et al., 2001; Pannu et al., 2008) , enhance fibroblast migration and adhesion (Lewis and Schwartz, 1998; Renshawa et al., 2000; Rajkumar et al., 2006) , stimulate epithelial mesenchymal transition (He, 2006) , and mediate the profibrotic activation of hepatic stellate c-Abl-mediated TGF-b responses via Egr-1 S Bhattacharyya et al cells in response to acetaldehyde (Ceni et al., 2006) . Furthermore, pathological tissue fibrosis is associated with in situ activation of c-Abl, as seen in the lesional dermis from mice with bleomycin-induced scleroderma and from patients with early active scleroderma . Inhibition of c-Abl activity might therefore explain the antifibrotic effects of imatinib as shown in mouse models of renal, lung and skin fibrosis (Daniels et al., 2004; Wang et al., 2005; Distler et al., 2007) .
Whereas Egr-1 is normally low to undetectable in most tissues, its expression is upregulated in lesional skin and lung tissues from mice with bleomycin-induced scleroderma (Bhattacharyya et al., 2008) . Furthermore, lesional skin and lungs, as well as explanted dermal fibroblasts, from patients with active scleroderma show elevated Egr-1 expression (Bhattacharyya et al., 2008) . The present results show that bleomycin-induced scleroderma was accompanied by elevated Abl phosphorylation in lesional dermal fibroblasts that correlated with elevated Egr-1 expression. Therefore, sustained in situ c-Abl activation might be a mechanism for inducing local Egr-1 expression or activity that contributes to the fibrotic process.
In summary, these results show that the oncogene c-Abl is activated by TGF-b in fibroblasts, and in turn is both necessary and sufficient for induction of Egr-1. Whereas TGF-b-mediated induction of Egr-1 is important for the stimulation of collagen gene expression, and was shown previously to involve a canonical ERK1/ 2 signal transduction mechanism associated with stress regulation of Egr-1, the events upstream of MEK1/ ERK1/2 in this pathway were hitherto unknown. Here, we show that c-Abl is upstream of Egr-1 in the stimulation of collagen gene expression by TGF-b. Activation of the c-Abl-Egr-1 pathway, presumably through PI3 kinase and PAK2 (Wilkes and Leof, 2006) , thus represents an important novel mechanism for mediating TGF-b responses in fibroblasts. These findings also indicate that diverse stimuli that elicit Egr-1 induction, including cellular stress and TGF-b, converge on c-Abl. Importantly, c-Abl-Egr-1-mediated stimulation of collagen gene expression appears to be independent of the Smad pathway, and occurs in mesenchymal, but not epithelial, cells. Unchecked TGF-b activity in pathological tissue repair might be associated with aberrantly sustained c-Abl activation, leading to ERK1/2-dependent upregulation and persistent expression of Egr-1 in fibroblasts. Sustained Egr-1 expression in target tissues in turn would induce or perpetuate fibrotic responses. Precise delineation of the components of this signaling mechanism is likely to yield further insights into the pathogenesis of fibrosis, and lead to the identification of novel targets for therapy.
Materials and methods
Cell culture and reagents Primary cultures of human dermal fibroblasts were established by explantation from neonatal foreskin and studied at early passages (o8) (Mori et al., 2004) . Murine NIH3T3 fibroblasts were obtained from the American Type Culture Collection (Mansassas, VA). Wild-type and Egr-1-null (Egr-1 À/À ) fibroblasts were established by explantation from neonatal mouse skin and studied at early passages. Abl-null/Arg-null (Abl
) MEFs stably expressing wild-type c-Abl or a kinase-inactive form of c-Abl were a gift from Woodring et al.(2002) . Fibroblasts were maintained in modified Eagle's medium or Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Gibco BRL, Grand Island, NY, USA), 1% vitamin and 2 mM L-glutamine. Culture media and tissue culture reagents were from Biowhittaker (Walkersville, MD, USA). In selected experiments, fibroblasts were incubated in serum-free media supplemented with 0.1% bovine serum albumin for 24 h before treatment. The kinase inhibitors imatinib mesylate (Novartis Pharmaceuticals, St Louis, MO, USA) or U0126 (Cell Signaling, Beverly, MA, USA) were added to the cultures for 30 min, followed by TGF-b1 (12.5 ng/ml) (PeproTech, Rocky Hill, NJ, USA) for up to 48 h. Cellular toxicity was evaluated by Trypan blue dye exclusion.
Quantitative real-time PCR Total RNA was isolated from fibroblasts using Trizol reagent (Life Technologies, Grand Island, NY). For qPCR, 1 mg of total RNA was reverse transcribed to cDNA using reverse transcription system (Promega, Madison, WI, USA), and products (50 ng) were amplified using SYBR Green PCR Master Mix (Applied Biosytems, Foster City, CA, USA) on the Applied Biosystems and 7500 Prism Sequence Detection System (Bhattacharyya et al., 2008) . The primers used are shown in Table 1 .
Western blot analysis
At the end of the experiments, whole cell lysates or nuclear and cytoplasmic extracts were prepared, and subjected to immunoblot analysis, as described previously (Mori et al., 2000) . In brief, equal amounts of proteins (20-50 mg/lane) were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 4-15% gels, proteins were transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA) and immunoblotted overnight with primary antibodies specific for Type I collagen (Southern Biotech, Birmingham, AL, USA), a-tubulin (both from Sigma-Aldrich, St Louis, MO, USA), c-Abl and phospho-cAbl, phospho-Smad2 and phospho-Smad3 (all from Cell Signaling, Beverly, MA), Egr-1(C19), or actin (C-2) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were then incubated with appropriate secondary antibodies and subjected to enhanced chemiluminescence detection using ECL Reagent (AmershamPharmacia, Piscataway, NJ, USA).
DNA affinity precipitation assays Nuclear extracts were prepared from confluent fibroblasts incubated with imatinib (10 mM) and TGF-b1 for 90 min, and subjected to DNA affinity precipitation assays, as described by Chen et al. (2006) . Briefly, synthetic double-stranded oligonucleotides corresponding to the consensus SBE sequence were biotinylated at the 5 0 end, and incubated with nuclear extracts in a binding mixture containing Streptavidin-agarose bead, followed by centrifugation. The bound proteins were separated by 4-20% SDS-PAGE, transferred to immobilon-P membranes, and immunoblotted with antibodies specific for phospho-Smad2 or phospho-Smad3 (Cell Signaling), followed by visualization using enhanced chemiluminescence (ECL) reagent.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were performed using Ez-Magna CHIP G (Millipore) according to the manufacc-Abl-mediated TGF-b responses via Egr-1 S Bhattacharyya et al turer's protocol. Briefly, confluent cultures of skin fibroblasts transfected with Bcr-Abl or empty vector were incubated with imatinib in the presence of TGF-b1 (10 ng/ml) for 60 min. Formaldehyde was added to the cultures (final concentration 1%) to cross-link chromatin. Nuclear extracts were then prepared and sonicated on ice to generate chromatin DNA fragments with an average length of 500-1000 bp. Aliquots of lysates were immunoprecipitated with antibodies to Egr-1 (588, Santa Cruz). Immunoprecipitated chromatin was recovered, and PCR amplification of the captured DNA sequences was performed using primers complementary to the COL1A2 promoter region harboring the Egr-1-binding sites À141 to À133 bp and distal À303 to À295 bp. The primer sequences were forward primer, 5 0 -CTACAGGGCACAGGTGAGG-3 0 , and reverse primer, 5 0 -AAAGCCCGGATCTGCCCTA-3 0 , to generate a 422-bp amplification product (Chen SJ, JBC) . DNA samples were analyzed by electrophoresis in 2% agarose gels.
Transient transfection assays
The reporter plasmids 772COL1A2-CAT (containing the -772/ þ 58 bp fragment of the human proa2 (I) collagen gene) (Ihn et al., 1997) and plasmids harboring 1.2 kb of the mouse Egr-1 gene promoter fused to luciferase gene (Sukhatme et al., 1988) were used for transient transfection assays. Subconfluent cultures of foreskin fibroblasts, NIH3T3 fibroblasts, or MEFs in media containing 0.1% fetal bovine serum or 0.1% bovine serum albumin and no serum were transfected using Superfect reagent (Qiagen, Valencia, CA, USA). In each experiment, fibroblasts were cotransfected with Renilla luciferase pRL-TK plasmids (Promega) as control for transfection efficiency. Fibroblasts were pretreated with imatinib (10 mM) or U0126 (10 mM) for 30 min, followed by incubation with TGF-b1 (10 ng/ml). At the end of the experiments, cultures were harvested and cell lysates were assayed for their luciferase or CAT activities (Chen et al., 1999) . Experiments were performed in triplicates and repeated at least two times.
c-Abl kinase assays
The regulation of cellular c-Abl activity was determined by in vitro kinase assays (Wilkes and Leof, 2006) . Briefly, cultures incubated with TGF-b1 for indicated periods were lysed in kinase buffer (Wilkes, 2004) . Cellular c-Abl was immunoprecipitated using antibody (K12; Santa Cruz Biotechnology), immune complexes were collected with protein A-Sepharose, washed twice in kinase buffer and then incubated in kinase buffer containing 0.5 mci [g 32 P] ATP. The reaction was allowed to proceed for 5 min, then was stopped and the complexes were subjected to SDS-PAGE, followed by autoradiography to examine the amount of phosphorylated GST-Crk substrate. Total c-Abl protein was detected by western blot analysis.
Immunofluorescence confocal microscopy Endogenous Smad localization was examined by immunofluorescence laser scanning microscopy (Mori et al., 2000) . Briefly, subconfluent foreskin fibroblasts or MEFs in media with 0.1% fetal bovine serum were pretreated with indicated concentrations of imatinib, followed by TGF-b1 (2.5 ng/ml) for 30 min or 24 h. Cultures were then fixed with 100% methanol and incubated with primary antibodies to Type I collagen (Southern Biotech), or to Smad1/2/3 or Smad4 (both from Santa Cruz), followed by fluorescin-5-isothiocyanate (FITC)-labeled secondary antibodies. Nuclei were identified by 4,6-diamidino-2-phenylindone. Subcellular distribution of fluorescence was evaluated by laser scanning confocal microscopy using a Zeiss LSHS10 microscope.
Expression of phospho-cAbl in vivo
To evaluate activation of c-Abl in vivo, six week-old female BALB/c mice (five mice per group) weighing 20 g received daily s.c. injections of bleomycin (Nihon Kayoku, Tokyo, Japan) or PBS (Lakos et al., 2004) . Twenty eight days after initiation of injections, mice were sacrificed, and lesional skin was harvested and processed for analysis (Takagawa et al., 2000) . Briefly, four mm sections were deparaffinized, rehydrated and incubated with peroxidase blocking solution (DAKO Corporation, Carpinteria, CA, USA) followed by rabbit polyclonal antibodies to phospho-cAbl (Cell Signaling) at a dilution 1:100, and donkey anti-rabbit IgG (Promega) as secondary antibodies at a dilution of 1:1000. Bound antibodies were detected using DAKO Envision þ System following the manufacturer's instructions. Substitution of the primary antibody with isotype-matched irrelevant IgG (Invitrogen, Carlsbad, CA, USA) at the same concentration served as negative control in every case. After counterstaining with hematoxylin, 
Statistical analysis
For comparisons of the means in control and treated fibroblasts, statistical significance was determined using the unpaired Student's t-test. A P-value o0.05 was considered significant.
